659PAvelumab (anti–PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from the phase Ib JAVELIN solid tumour JPN trial. (23rd October 2018) - Doi, T; Iwasa, S; Muro, K; Satoh, T; Hironaka, S; Esaki, T; Nishina, T; Hara, H; Machida, N; Komatsu, Y; Shimada, Y; Otsu, S; et al.